Key players in the Peptide Therapeutics in Metabolic Disorders Market:
Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.
Peptide Therapeutics In Metabolic Disorders Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients